FRI0021 Calprotectin Levels Correlate with Inflammation in Early RA before dMARD Treatment and after 12 Months of Treatment: Table 1
| Autor: | Anna-Birgitte Aga, Karl A. Brokstad, M.K. Jonsson, Inge C. Olsen, Hilde Berner Hammer, Siri Lillegraven, Hilde Haugedal Nordal, B.-T.S. Fevang, Espen A Haavardsholm, T.K. Kvien |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty medicine.diagnostic_test business.industry Immunology Inflammation medicine.disease Gastroenterology General Biochemistry Genetics and Molecular Biology Surgery The arctic S100A8 Rheumatology Internal medicine Erythrocyte sedimentation rate Rheumatoid arthritis Early ra medicine Immunology and Allergy In patient medicine.symptom Calprotectin business |
| Zdroj: | Annals of the Rheumatic Diseases. 75:433.1-433 |
| ISSN: | 1468-2060 0003-4967 |
| Popis: | Background Calprotectin (MRP8/MRP14, S100A8/A9) is a major leukocyte protein previously shown to be associated with disease activity in patients with established rheumatoid arthritis (RA), and some studies indicate that it may be a more accurate measure of joint inflammation than erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Objectives To compare the associations of calprotectin, ESR and CRP to clinical and ultrasound measures of inflammation in patients with early RA, both before and after 12 months of aggressive disease-modifying antirheumatic drug (DMARD) treatment. Methods RA-patients (n=238) who fulfilled the 2010 ACR/EULAR classification criteria were recruited to the ARCTIC trial between 2010 and 2013. All patients had symptom duration from first swollen joint Results A total of 217 patients were included: 61% female, 71% RF positive, 82% ACPA positive, mean (SD) age 53.5 (13.7) years, mean DAS 3.46 (1.17), median [25, 75 percentile] disease duration 5.7 [2.8, 10.4] months. At 12 months mean DAS was 1.25 (0.72); 74% were in remission according to DAS, 17% low, 9% moderate and 0% high DAS. The median baseline/12 month calprotectin was 1028 [567, 2158]/485 [293, 802] μg/L, ESR 19 [11, 31]/9 [5, 14] mm/h and CRP 7 [3, 18]/3 [1, 5] mg/L. Calprotectin was significantly correlated to clinical, laboratory and US measures of inflammation before treatment onset (table). After 12 months of treatment, calprotectin had a weaker, but statistically significant correlation to US scores, while no association between ESR/CRP and US scores was found. Conclusions Calprotectin was correlated to inflammation assessed by ultrasound before onset of DMARD treatment, and the association was also present after 12 months of DMARD treatment. The data support that calprotectin might be of interest when assessing disease activity in different stages of RA. References Hammer HB et al Ann Rheum Dis 2011 Acknowledgement We would like to thank Inge Dale at CalproLab and Marianne Eidsheim at Broegelmann Research Laboratory. Disclosure of Interest M. Jonsson: None declared, H. Hammer Speakers bureau: AbbVie, Roche, Pfizer, UCB, BMS, H. Nordal: None declared, A.-B. Aga: None declared, I. Olsen: None declared, K. Brokstad: None declared, B.-T. Fevang: None declared, T. Kvien Grant/research support from: AbbVie, BMS, MSD, Pfizer, Roche, UCB, Speakers bureau: AbbVie, BMS, Celgene, Celltrion, Eli Lilly, Hospira, Merck-Serono, MSD, Novartis, Orion Pharma, Pfizer, Roche, Sandoz, UCB, S. Lillegraven: None declared, E. Haavardsholm Grant/research support from: AbbVie, MSD, Pfizer, Roche, UCB |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|